

1 Article

2 Increased Plasma Levels of Gut-Derived Phenolics Linked to 3 Walking and Running Following 2-Weeks Flavonoid 4 Supplementation

5 David C. Nieman^{1*}, Colin D. Kay,² Atul S. Rathore², Mary H. Grace², Renee C. Strauch²,
6 Ella H. Stephan¹, Camila A. Sakaguchi¹, Mary Ann Lila²

7 ¹ Human Performance Laboratory, Appalachian State University, North Carolina Research Campus,
8 Kannapolis, North Carolina, USA; niemandc@appstate.edu (D.C.N.); estephan@email.unc.edu (E.H.S.);
9 camila.sakaguchi@hotmail.com (C.A.S.).

10 ² Food Bioprocessing and Nutrition Sciences, Plants for Human Health Institute, North Carolina State
11 University, North Carolina Research Campus, Kannapolis, North Carolina, USA; cdkay@ncsu.edu
12 (C.D.K.); asrathor@ncsu.edu (A.S.R.); mhgrace@ncsu.edu (M.H.G.); rcstrauc@ncsu.edu (R.C.S.);
13 mlila@ncsu.edu (M.A.L.).

14 * Correspondence: niemandc@appstate.edu; Tel.: +1-828-773-0056

15

16 Abstract

17 Using a randomized, double-blinded, placebo-controlled, parallel group design, this
18 investigation determined if the combination of 2-weeks flavonoid supplementation (329 mg/day,
19 quercetin, anthocyanins, flavan-3-ols mixture) and a 45-minute walking bout ($62.2 \pm 0.9\%$ $\text{VO}_{2\text{max}}$)
20 enhanced the translocation of gut-derived phenolics into circulation in a group of walkers (N=77).
21 The walkers (flavonoid, placebo groups) were randomized to either sit or walk briskly on
22 treadmills for 45 minutes (thus four groups: placebo-sit, placebo-walk, flavonoid-sit, flavonoid-
23 walk). A comparator group of runners (N=19) ingested a double flavonoid dose for 2 weeks (658
24 mg/day) and ran for 2.5 h ($69.2 \pm 1.2\%$ $\text{VO}_{2\text{max}}$). Four blood samples were collected (pre- and post-
25 supplementation, immediately-post- and 24-h post-exercise/rest). Of the 76 metabolites detected in
26 this targeted analysis, 15 increased after the 2.5-h run, and when grouped were also elevated post-
27 exercise (versus placebo-sit) for the placebo- and flavonoid-walking groups ($P < 0.05$). A secondary
28 analysis showed that pre-study plasma concentrations of gut-derived phenolics in the runners were
29 40% higher compared to walkers ($P = 0.031$). These data indicate that acute exercise bouts (brisk
30 walking, intensive running) are linked to an increased translocation of gut-derived phenolics into
31 circulation, an effect that is amplified when combined with a 2-week period of increased flavonoid
32 intake or chronic training as a runner.

33 **Keywords:** exercise, polyphenol, metabolite, hippurate, intestinal tract, colon

34

35 1. Introduction

36 Small amounts of flavonoids from ingested foods and beverages are absorbed in the small
37 intestine [1]. A much larger proportion of ingested flavonoids, however remain unabsorbed and
38 persist in the lower intestine for long periods of time, where they experience microbial degradation
39 (including ring fission), forming a diversity of phenolic compounds that can be absorbed, undergo
40 phase II metabolism, and exert a variety of bioactive effects before elimination in the urine.

41 In a previous 17-day study using a supplement with blueberry and green tea flavonoids,
42 vigorous exercise significantly increased the translocation of gut-derived phenolics into the blood
43 compartment [2]. This study, however, used an untargeted metabolomics approach that was not
44 optimized to detect the diversity of gut-derived flavonoid metabolites as reported in recent
45 literature.

46 Exercise has been linked in many studies to a transient increase in gut permeability, an effect
47 that can occur after just 20 minutes of vigorous exercise [3,4]. In exercise-based studies, whole gut
48 permeability is commonly measured using the ratio of lactulose and mannitol sugars in the urine. A
49 transient increase in gut permeability has been speculated as a possible mechanism by which

50 vigorous exercise accelerates the movement of beneficial gut-derived phenolics from the lower
51 intestine into the blood [5]. An alternative hypothesis is that moderate- and high-intensity exercise
52 may influence the activity of transporters that control the movement of flavonoids and their
53 transformed metabolites across the wall of the gastrointestinal tract into circulation. In one study,
54 urinary excretion of microbial phenolic metabolites was higher during exercise training compared
55 to a week of no training in 10 endurance trained males [6]. Taken together, the limited data
56 available suggest that plasma levels of gut-derived phenolics may be linked to both chronic and
57 acute exercise influences.

58 Using a randomized, parallel group design, this investigation determined if the combination of
59 2-weeks flavonoid supplementation (329 mg/day) and one acute 45-minute brisk walking bout (70%
60 VO_{2max}) enhanced the translocation of gut-derived phenolics into the circulation in a group of
61 healthy walkers (N=77). A comparator group of trained runners (N=19) ingesting a double dose of
62 the flavonoid supplement for two weeks was included (2.5 h run, 70% VO_{2max}). A secondary
63 analysis compared pre-study plasma levels of gut-derived phenolics in the groups of walkers and
64 runners. A key feature of this study was the use of a targeted metabolite analysis protocol that had
65 been optimized and validated to detect and quantify 121 analytes relative to 75 commercial and
66 synthetic reference standards.

67 2. Materials and Methods

68 2.1 Participants

69 Healthy males and females with a history of regular walking (>100 minutes per week), a body
70 mass index (BMI) less than 35 kg/m², and 18 to 50 years of age (N=81), were entered into the study
71 and randomized to the flavonoid or placebo supplement groups for 2 weeks. A total of 77 of these
72 participants completed all phases of the study. Male and female runners (N=21) with a history of
73 participating in 10 km to 42.2 km races and the ability to run for 2.5 h on a treadmill in a laboratory
74 setting were entered into the study as a comparator group. A total of N=19 runners completed all
75 phases of the study. All study participants agreed to consume less than 5 servings/day of fruits and
76 vegetables, less than 2 cups/day coffee, and no green tea during the 2-week study. Study participants
77 also agreed to avoid use of non-steroidal anti-inflammatory drugs (NSAIDs), and all dietary and
78 herbal supplements during the 2-week study. Participants voluntarily signed the informed consent,
79 with study procedures approved by the university Institutional Review Board.

81 2.2 Research Design

82 This study utilized a randomized, parallel group design. Supplements for the walking group
83 were administered in a double-blinded manner in capsule form. Study participants reported to the
84 research facility for baseline testing and orientation, and then pre-study and after 2-weeks
85 supplementation, and then again 24 hour later. Four blood samples were collected (pre- and post-
86 supplementation, post-exercise/rest, and 24-hour post-exercise/rest). When reporting to the lab
87 after 2-weeks supplementation, study participants were randomized to either sit or walk briskly on
88 treadmills for 45 minutes. A comparator group of 20 runners ingested a double dose of the
89 flavonoid supplement for 2-weeks, and then ran on treadmills for 2.5 h in the laboratory.

90 One to two weeks before the start of the study, study participants (walkers and runners) were
91 given an orientation to the study. Instructions were given for recording all food and beverage intake
92 in 3-day food logs (Thursday, Friday, and Saturday prior to starting supplementation). Demographic
93 and training histories were acquired with questionnaires. Height, body weight, and percent body
94 fat were measured (seca Medical Body Composition Analyzer 514 bioelectrical impedance scale,
95 Hanover, MD). VO_{2max} was assessed using the Bruce's treadmill protocol, with oxygen consumption
96 and ventilation continuously monitored using the Cosmed CPET metabolic system (Rome, Italy).

97 On the first day of the 2-week supplementation period, participants (walkers and runners)
98 returned to the lab in a fasted state (9 or more hours with no food or beverage other than water).
99 Blood samples were taken from an antecubital vein with subjects in the seated position. Participants
100 (walkers) were given a 2-week supply of flavonoid or placebo capsules organized into supplement
101 trays to facilitate compliance. Runners were given a 2-week supply of flavonoid capsules in
102 supplement trays. The 3-day food record was turned in and reviewed by the research team, and
103 analyzed for nutrient and flavonoid content using the Food Processor v. 11.1 (ESHA Research, Salem,
104 OR). ESHA's port utility (v. 4.0) was used to upload the Flavonoid Values for USDA Survey Foods
105 and Beverages (FNDDS) 2007-2010 database [7]. Each food/beverage was assessed for macro- and
106 micro-nutrients, total flavonoids and subtotals for each of the six flavonoid subclasses, and three
107 individual flavonoid values (quercetin, cyanidin, and epigallocatechin gallate (EGCG)).

108 After the 2-week supplementation period, participants (walkers and runners) returned to the lab
109 in an overnight fasted state (on the same day of the week as the pre-supplementation lab visit).
110 Participants turned in the supplement tray to verify compliance to the supplementation regimen. A
111 blood sample was collected. Participants (walkers) were then randomized to either sit for 45 minutes
112 in the lab or to walk briskly for 45 minutes on a 5% graded treadmill at 60% VO_{2max} (with metabolic
113 monitoring during the first 5 minutes, and then at 15, 30, and 45 minutes) using the Cosmed CPET
114 metabolic cart. Runners ran at 70% VO_{2max} on an ungraded treadmill for 2.5 h, with metabolic
115 measurements made every 30 minutes. Water was given ad libitum for all participants, with no other
116 beverage or food allowed.

117 Just prior to the sitting or walking lab sessions, and the 2.5 h run, participants consumed a 150-
118 ml solution containing 1 g lactulose and 0.5 g mannitol (as markers of gastric permeability). An
119 increase in the lactulose/mannitol ratio (L/M) was used as an indicator of increased gut permeability.
120 The normal rate of absorption is approximately 10% for mannitol and less than 1% for lactulose.
121 When gut permeability rises, lactulose absorption increases disproportionately to mannitol (i.e., an
122 increase in L/M)[8,9]. Urine was collected in a plastic container for five hours after ingesting the sugar
123 mixture. No eating or drinking (except tap water) was allowed during the 5-h urine collection.
124 Participants returned the next morning in an overnight fasted state, provided a blood sample, and
125 turned in the urine sample.

126 Supplement and placebo capsules were prepared by Reoxcyn LLC (Pleasant Grove, UT, USA).
127 Supplement ingredients (US Patent 9,839,624) included the following (in 2 capsules) and provided
128 329 mg total monomeric flavonoids: 100 mg vitamin C (as ascorbyl palmitate) (Green Wave
129 Ingredients, La Mirada, CA, USA), wild bilberry fruit extract with 64 mg anthocyanins
130 (FutureCeuticals, Momence, IL, USA), green tea leaf extract with 184 mg total flavan-3-ols (Watson
131 Industries, Inc., Pomona, CA, USA), 104 mg quercetin aglycone (Novel Ingredients, East Hanover,
132 NJ, USA), 107 mg caffeine (Creative Compounds, Scott City, MO, USA), and 60 mg omega 3 fatty
133 acids (Novotech Nutraceuticals, Ventura, CA, USA). Capsule fill ingredients and excipients include
134 Nu-Flow 70R (from rice hulls), tapioca from cassava root, natural bamboo silica, and marshmallow
135 root. Placebo capsules contained only the fill ingredients and excipients (without the active
136 ingredients).

137 As previously reported, the capsule contents were analyzed prior to the study for flavonoid
138 content using high-performance liquid chromatography (HPLC) [10]. The flavonoid content was
139 calculated as the sum of anthocyanins (measured as cyanidin-3-glucoside equivalents), quercetin,
140 and flavan-3-ol compounds [epigallocatechin gallate (EGCG), epicatechin, epigallocatechin, and
141 epicatechin gallate].

142 The daily serving for the walkers was 2 flavonoid (329 mg/day) or 2 placebo capsules. The daily
143 serving for the runners was 4 flavonoid capsules (658 mg/day). Participants were given a 2-week
144 supply of either the flavonoid or placebo capsules, with instructions on how to consume the capsules
145 daily in split doses (1 with breakfast and 1 with lunch, or double that amount for the runners. Study
146 participants ingested 2 capsules (4 for the runners) just after providing the blood sample during the
147 walk/rest (or run) lab session.

148

149 2.3 Analytical Methods

150

151 2.3.1 Targeted Metabolomics Analysis

152 Gut-derived phenolic metabolites were purified from 100 μ L plasma by 96-well solid phase
153 extraction (SPE; Strata™-X Polymeric Reversed Phase, microelution 2 mg/well). 75 commercially
154 available and synthetic reference standards were purchased from: Alfa Aesar (Tewksbury, MA,
155 USA), Ark Pharm (Libertyville, IL, USA), Biovision (San Francisco, CA, USA), Chromadex (Irvine,
156 CA, USA), Extrasynthese SA (Z.I Lyon Nord, France), Fisher Scientific (Waltham, MA, USA), Matrix
157 Scientific (Columbia, SC, USA), Oxchem (Wood Dale, IL, USA), PhytoLab GmbH & Co. KG
158 (Vestenbergsgreuth, Germany), Polyphenols AS (Sandnes, Norway), Sigma (St. Louis, MO, USA),
159 TCI America (Portland, Oregon, USA), Toronto Research Chemicals (Toronto, Canada) and
160 synthesized in a project sponsored by the BBSRC (BB/I0066028/1). (See supplemental Table S1).
161 Reference standards had been previously optimized for UPLC-MS/MS parameters ($CV \leq 15$) with
162 extraction efficiencies between 80-100% recoveries. Extracts were separated and quantified via liquid
163 chromatography tandem-MS/MS. Briefly, HPLC-ESI-MS/MS analysis was performed using SCIEX
164 QTRAP 6500+ enhanced high performance hybrid triple quadrupole-linear ion trap mass
165 spectrometer with electrospray IonDrive Turbo V Source coupled to an Exion high performance
166 UHPLC, with samples injected onto a Kinetex PFP UPLC column (1.7 μ m particle size, 100 \AA pore

167 size, 100mm length, 2.1mm internal diameter; Phenomenex®) with oven temperature maintained at
168 37°C. Mobile phase pump A was comprised of 0.1% v.v. formic acid in water (Optima grade, Fisher
169 Scientific) and pump B 0.1% v.v. formic acid in LC-MS grade acetonitrile (Honeywell Burdick and
170 Jackson, Muskegon, MI, USA), with binary gradient from 2% B to 90% B over 30 min and flow rate
171 gradient ranging from 0.55 mL/min to 0.75 mL/min. MS/MS scanning was achieved via advanced
172 scheduled multiple-reaction monitoring (ADsMRM) using positive and negative ionization mode
173 toggling in Analyst (v.1.6.3, SCIEX) with quantitation conducted using MultiQuant (v.3.0.2, SCIEX)
174 software platforms. Internal standards included L-tyrosine-¹³C₉,¹⁵N, resveratrol-(4-hydroxyphenyl-
175 ¹³C₆), and phloridzin dehydrate (Sigma-Aldrich) and 12-point calibration curves (1nM to 100µM)
176 were established using reference standards in a matched matrix [SPE extracted Corning pooled
177 healthy donor Human AB Serum (# 35-060-CL, Mediatech Incorporated)]. Source parameters
178 included: curtain gas 35, ion-spray voltage 4000, temperature 550, nebulizer gas 70, heater gas 70, and
179 with optimized analyte specific quadrupole voltages (mean±SD) between 40±24 for declustering
180 potential (min 4.5 to 185), 10±1 for entrance potential (min 3 to max 13), 26±11 for collision energy
181 (min 5 to max 59), and 14±10 for collision cell exit potential (min 1 to max 51).

182 The targeted metabolite analysis protocol was optimized and validated to detect 121 analytes,
183 which were quantified relative to 75 authentic commercial and synthetic standards. Where reference
184 standards for metabolites (including Phase II conjugates) were not available (46 analytes),
185 identification was based on fragmentation profiling involving the precursor structure and 3-5
186 product transitions, and confirmed in pooled samples. These metabolites were then quantified
187 relative to their closest structural reference standard with similar ionization intensities (Supplement
188 Table S1). Finally, all metabolites were confirmed on the basis of established retention times (using
189 authentic and synthesized standards where possible) and three or more precursor-to-product ion
190 transitions.

191 192 2.3.2 Urine Sugar Analysis

193 Reference standards for lactulose and mannitol were purchased from Sigma Aldrich and an
194 internal standard, [UL-¹³C₆glc]-Sucrose, was purchased from Omicron Biochemicals, Inc (South
195 Bend, IN, USA). All standards were optimized and validated for UPLC-MS/MS parameters and
196 sugars in urine were quantified relative to authentic commercial standards. Samples from each
197 treatment group and time point were pooled and a 1:100 dilution was prepared with 90% acetonitrile.
198 Samples were separated and quantified via UPLC-MS/MS. Briefly, UPLC-ESI-MS/MS analysis was
199 performed using a Waters Xevo G2-XS QTOF mass spectrometer with a LockSpray source and ESI
200 probe coupled to an ACQUITY I-Class UPLC.

201 Samples were injected onto a Luna NH₂ column (3 µm particle size, 100 Å pore size, 100 mm
202 length, 2 mm internal diameter; Phenomenex®) with column temperature maintained at 30 °C.
203 Mobile phase A was comprised of 0.1% v.v. formic acid in water (Honeywell, LC-MS grade), Mobile
204 phase B was comprised of 0.1% v.v. formic acid in acetonitrile (Honeywell, LC-MS grade). The
205 binary gradient ranged from 95% B to 20% B over 7.5 minutes with a flow rate of 0.7 mL/min.
206 MS/MS scanning was achieved via Tof-MRM with target enhancement using negative ionization
207 mode in MassLynx (v 4.1) with quantitation performed using TargetLynx (v 4.1) software platforms.
208 10 point calibration curves (from 1 nM to 5 µM for lactulose, and 39 nM to 150 µM for mannitol) were
209 established using reference standards in a matched (negative control) matrix (Surine™ Negative
210 Urine Control, Certified Reference Material, Sigma Aldrich). Source parameters included: Capillary
211 voltage 1.00 kV, Sampling cone 50-70 (arbitrary units, analyte dependent), Source offset 80 (arbitrary
212 units), Source temperature 150 °C, Desolvation gas temperature 600 °C, Cone gas flow 50 L/h,
213 Desolvation Gas Flow 1200 L/h, collision energy 6-10 (analyte dependent). The lactulose/mannitol
214 ratio was used as an indicator for small and large intestine permeability, respectively.

215 216 2.4 Statistical Procedures

217 Data are presented as mean ± standard error (SE). Group comparisons between the walkers and
218 runners (subject characteristics, performance data, nutrient intake, and other selected variables) were
219 compared using student t-tests, with statistical differences accepted when the P-value was ≤0.05. The
220 plasma metabolite data (both single metabolites and grouped metabolites) were analyzed using the
221 generalized linear model (GLM), and a 5 (groups) × 4 (time) repeated-measures ANOVA, between-
222 participants design (IBM SPSS Statistics for Windows, Version 24.0, IBM Corp, Armonk, NY, USA).
223 When the interaction statistic was significant in the GLM analysis (P≤0.05), post-hoc analyses were
224 conducted with student t-tests comparing the change from pre-study values over time against the

225 placebo-sit group. For these analyses, statistical differences were accepted when the P-value was ≤
226 0.017.

227 3. Results

228 The analysis included 77 walkers and 19 runners who successfully adhered to all aspects of the
229 study design (Table 1). The walkers and runners did not differ in age or maximal heart rates. The
230 runners versus walkers had significantly higher maximal oxygen consumption rates (VO_{2max}) (male
231 and female runners, 49% and 43% higher, respectively) and lower body fat percentages. A separate
232 analysis of the four subgroups randomized among the N=77 walkers [placebo-sit (N=16), placebo-
233 walk (N=20), flavonoid-sit (N=20), flavonoid-walk (N=21),] showed no significant differences for any
234 of the variables listed in Table 1.
235
236

Table 1. Subject characteristics.

Subjects Variable	Walkers (N=77, 18M, 59F) Mean±SE	Runners (N=19, 13M, 6F) Mean±SE	P-value M:F walkers, M:F runners M walk:run, F walk:run
Age (y)	M:36.2±2.5; F:37.2±1.2	M:35.4±2.0; F:39.7±1.6	0.710, 0.189; 0.807, 0.533
Height (cm)	M:178±1.5; F:165±0.8*	M:176±1.5; F:163±3.7*	<0.001, <0.001; 0.268, 0.370
Weight (kg)	M:87.7±3.1; F:70.2±1.6*	M:72.9±3.5 [†] ; F:60.4±1.3*	<0.001, 0.029; 0.004, 0.062
Body fat (%)	M:24.3±1.7; F:32.3±0.9*	M:14.5±1.6 [†] ; F:26.2±1.5 ^{†*}	<0.001, <0.001; <0.001, 0.035
VO _{2max} (ml ⁻¹ ·kg ⁻¹ ·min)	M:39.5±2.1; F:34.2±1.1*	M:59.0±3.5 [†] ; F:48.9±2.6 [†]	0.027, 0.088; <0.001, <0.001
HR _{max} (beats/min)	M:178±3.3; F:176±1.6	M:177±5.3; F:174±2.2	0.557, 0.675; 0.852, 0.719
VE _{max} (L/min)	M:118±6.1; F:81.4±5.9*	M:137±8.6; F:93.4±5.6*	0.002, 0.005; 0.065, 0.524
RER _{max}	M:1.16±0.2; F:1.13±0.1	M:1.09±0.4 [†] ; F:1.09±0.4	0.166, 0.940; 0.035, 0.279


237 * P<0.05 M vs F; † P<0.05 walkers vs runners within gender. M = males; F = females; VO_{2max} = maximal oxygen
238 consumption rate; HR_{max} = maximal heart rate; VE_{max} = maximal ventilation; RER_{max} = the maximal respiratory
239 exchange ratio or VCO₂/VO₂.
240

241 Three-day food records collected before the study began revealed no significant group
242 differences (walkers and runners, and the four walker subgroups) in energy, macronutrient,
243 micronutrient intake, and total flavonoid intake (data not shown). Total flavonoid intake was
244 relatively low [7] for both the walkers and runners (105±12.0, 56.1±15.0 mg/day, respectively, P=0.08),
245 with no group differences for the six flavonoid subgroups (anthocyanins, flavan-3-ols, flavonols,
246 flavanones, isoflavones, flavones) and specific flavonoids (cyanidin, EGCG, quercetin). The 2-week
247 flavonoid supplementation regimen did not significantly increase fasting plasma gut-phenolic levels
248 (average of all 76 metabolites detected) compared to placebo (2.19±1.48 μM, -0.45±1.24 μM,
249 respectively, P=0.185) in the study participants from the walking groups. Overnight fasted plasma
250 hippuric acid levels did increase significantly in the runner (658 mg flavonoids/day) versus placebo-
251 sit group (329 mg flavonoids/day) as depicted in Figure 1 (P=0.004).

252 Table 2 summarizes the performance data for the 41 walkers randomized to the 45-minute
253 walking bout and the 19 runners who ran for 2.5 hours on treadmills. Absolute and relative oxygen
254 consumption and heart rates were significantly higher, as designed, during the running compared to
255 walking bouts.

256 Figure 2 summarizes the lactulose/mannitol ratios (L/M) measured from pooled urine samples
257 (collected for 5 hours after sugar ingestion) for each of the five groups. L/M was 33% higher in the

258 runner group compared to the placebo-sit group, and 19%, 45%, and 35% lower in the placebo-walk,
 259 flavonoid-sit, and flavonoid walk groups, respectively.
 260




261 **Figure 1.** Plasma hippuric acid levels increased significantly in the flavonoid-run group compared to the
 262 placebo-sit group. Interaction effect, $P=0.023$; * $P<0.017$, change from pre-supplementation versus placebo-sit.
 263
 264

265 **Table 2.** Performance data for the 45-minute walking and 2.5-hour running sessions.
 266


Performance Variable	Walkers (N=41) (45 minutes)	Runners (N=19) (2.5 hours)
VO _{2avg} (L/min)	1.65±0.62	2.62±1.29*
VO ₂ (% max)	62.2±0.9	69.2±1.2*
HR _{avg} (bpm)	132±2.5	143±4.0*
HR (% max)	74.3±1.3	80.9±2.4*
RPE _{avg}	11.0±0.2	11.3±0.3
Weight change (kg)	0.08±0.09	-1.9±0.2*

267 * $P<0.05$, walkers versus runners



268 **Figure 2.** Lactulose/mannitol ratios from pooled urine (5 hours collection) for each of the five groups.
 269

270 Post-exercise elevations (from pre-supplementation levels) in metabolites detected
 271 (supplemental Table S2) were evaluated in the double-flavonoid dose runner group relative to the
 272 placebo-sit group and selected for secondary analysis where trends were observed (group contrasts,
 273 $P < 0.175$). Fifteen metabolites were identified, grouped, and compared between the 4-study groups
 274 and runner comparator group. Figure 3 shows that higher post-exercise changes (from pre-
 275 supplementation levels) were observed (compared to the placebo-sit group) for the placebo-walk,
 276 flavonoid-walk, and flavonoid-run groups. The 15 gut-derived phenolics included: hippuric acid, 3-
 277 hydroxyhippuric acid, 4-hydroxycinnamic acid, 5-(3',4'-dihydroxyphenyl)- γ -valerolactone, 4-
 278 hydroxy-3-methoxybenzoic acid, 4-hydroxybenzaldehyde, 3-methoxybenzoic acid-4-O-glucuronide,
 279 4-methoxybenzoic acid-3-O-glucuronide, 3-(3-hydroxy-4-methoxyphenyl)propanoic acid-3-O-
 280 glucuronide, quercetin-3-O-glucuronide and delphinidin glucoside, dihydroxybenzaldehyde
 281 glucuronide, hydroxy-methoxybenzyldehyde glucuronide, hydroxy-methoxybenzaldehyde sulfate
 282 and trihydroxy-benzaldehyde sulfate. See supplemental Table S1 for more information on these
 283 metabolites.




284 **Figure 3** Post-exercise change from pre-supplementation for 15 selected and grouped plasma gut-derived
 285 phenolics (µM) with P-values indicated relative to the placebo-sit group. Interaction effect, $P < 0.001$. P-values
 286 represent significance testing for the contrast in change (post-exercise from pre-supplementation) compared to
 287 the placebo-sit group.
 288


289
 290 Figure 4 depicts group comparisons across the four time points for one the 15 gut-derived
 291 phenolics (as an example) that increased after both walking and running relative to the placebo-sit
 292 group: 3-(3-hydroxy-4-methoxyphenyl)propanoic acid-3-O-glucuronide (interaction effect, $P < 0.001$).

293 A secondary analysis evaluated the effect of fitness status on pre-study plasma levels of the 76
 294 identified metabolites in runners ($N=19$) compared to the walkers ($N=77$) (Figure 5). The average
 295 plasma level of these metabolites in the runners was 40% higher than in the walkers ($P < 0.001$, Figure
 296 5A). An additional analysis showed that this difference was primarily driven by greater runner levels
 297 for 7 plasma gut-derived phenolics ($P < 0.001$): 4-hydroxyphenylacetic acid, 5-O-caffeoylquinic acid,
 298 5-O-feruloylquinic acid, 3,4-dihydroxycinnamic acid-4-O-glucuronide, pyridoxic acid sulfate,
 299 hydroxy-methoxyphenylacetic acid glucuronide, and dihydroxy-benzaldehyde glucuronide. Minor
 300 but significantly lower plasma levels of 32 metabolites were found in the runners (represented as
 301 orange stacked column bars; Figure 5B).
 302

303



314 **Figure 4** Plasma 3-(3-hydroxy-4-methoxyphenyl)propanoic acid-3-O-glucuronide increased significantly post-
 315 exercise (above pre-supplementation levels compared to the placebo-sit group) for both the flavonoid-walk and
 316 flavonoid-run groups. Interaction effect, $P < 0.001$; * $P < 0.017$.



317

318 **Figure 5** A) Pre-study sum of all 76 plasma gut-derived phenolics detected in the analysis; B) Pre-study group
 319 differences for 7 and 32 selected metabolites that were higher and lower, respectively, in the runners compared
 320 to the walkers.

321 4. Discussion

322 The data from this randomized, double-blinded, placebo-controlled, parallel group study with
 323 walkers (N=77) and a comparator group of runners (N=19) showed that the combination of 2-weeks
 324 flavonoid supplementation and exercise (both 45-min brisk walking and 2.5-h running) enhanced the
 325 translocation of gut-derived phenolics into the circulation. Of the 76 gut-derived phenolic metabolites
 326 detected, 15 were found to be most responsive to acute exercise, with higher post-exercise changes

327 measured (versus placebo-sit) for the placebo-walk, flavonoid-walk, and flavonoid-run groups. The
328 pre-study plasma concentration of the gut-derived phenolic metabolites (all 76 that were detected)
329 was 40% higher in the runners than in the walkers. These data indicate that acute exercise bouts (both
330 brisk walking and intensive running) combined with flavonoid supplementation, and the elevated
331 fitness status associated with habitual running, are linked to elevations in plasma levels of gut-
332 derived phenolics. There was no discernable increase in overnight fasted plasma levels of gut-derived
333 phenolics after the 2-week supplementation period, due in part to the >17-hour time period from the
334 previous day's flavonoid dose (morning, noon). The post-exercise increase in plasma levels of gut-
335 derived phenolics appears to be related to a true exercise effect, as supported by the post-exercise
336 increase observed in the placebo-walk group. However, the larger post-exercise increase in plasma
337 levels of gut-derived phenolics measured in the flavonoid-walk and flavonoid-run groups relative to
338 the other groups could also be related to the acute flavonoid dose ingested just prior to the exercise
339 sessions.

340 In a previous study, we showed that a 3-day period of intensive exercise (2.5 h running/day)
341 enhanced the plasma gut-derived phenolic signature following a 17-day period of high flavonoid
342 intake (blueberry and green tea extracts)[2]. Increases in plasma gut-derived phenolic metabolites
343 linked to bacterial metabolism included hippurate (1.8-fold) and 4-methylcatechol sulfate (2.5-fold),
344 and elevations persisted for at least 14-h post-exercise. Increases were also measured, albeit to a lesser
345 extent, for other similar metabolites including 2-hydroxyhippurate, 3-hydroxyhippurate, 4-
346 hydroxyhippurate, catechol sulfate, and O-methylcatechol-sulfate. The primary limitation of this
347 study was the use of an untargeted metabolomics approach with median scaled intensity values.
348 Also, the exercise regimen was unusually rigorous, with little transference value to the general
349 population. In the current study, we sought to extend these findings by including two types of
350 exercise modes and durations (45 minutes walking and 2.5 hours running), a moderate dose of a
351 diverse mixture of flavonoids (329 mg/day, 2-week period), and the utilization of a quantitative
352 targeted gut-derived phenolic metabolite analysis protocol optimized and validated using reference
353 standards.

354 The novel finding that the combination of increased flavonoid intake and moderate/vigorous
355 exercise was associated with an acute, transient increase in plasma gut-derived phenolic metabolites
356 could be due to several underlying mechanisms. These include increased gut permeability, a selective
357 change in gut transporter density and function, changes in gut microbiota population diversity, and
358 altered gastrointestinal motility and transport rate [6,11,12]. The relative importance of these various
359 factors in explaining study results remain to be determined in future investigations. The urine sugar
360 data (L/M) supported an increase in gut permeability following the 2.5-h running bout, but not the
361 walking bouts. To the contrary, the L/M ratio was substantially lower for the two flavonoid groups
362 (flavonoid-sit and flavonoid-walk) compared to the placebo-sit group. Flavonoids and their bio-
363 transformed metabolites exert direct effects within the gastrointestinal tract including maintenance
364 of intestinal barrier integrity [13,14]. Flavonoids play a role in protecting intestinal epithelial cells
365 from inflammation-induced permeabilization [15]. Prolonged and intensive running but not
366 moderate walking increases IL-6 and other cytokines that disrupt the intestinal tight junction barrier
367 and increase permeability [16,17]. Taken together, our data suggest that despite a 2-week period of
368 increased flavonoid intake, intensive and prolonged running was coupled with a post-exercise surge
369 in plasma gut-derived phenolic metabolites due in part to increased gut permeability. Although
370 speculative, the transient post-exercise elevation in circulating gut-derived phenolics may play a role
371 in diminishing inflammation and oxidative stress during recovery from intensive running [18].

372 The modest increase in plasma gut-derived phenolic metabolites following 2-weeks flavonoid
373 supplementation and the 45-minute brisk walking bout may have occurred through other
374 mechanisms including modifications in gut transporter localization, density and function. Flavonoid
375 absorption and distribution throughout the body are dependent on specific cell transport systems [1].
376 The SLC22 transporter family regulates multiple metabolic pathways and signaling molecules
377 including those related to gut microbiome products, tricarboxylic acid cycle intermediates, dietary
378 flavonoids, nutrients, prostaglandins, and short-chain fatty acids [19]. The combined influence of

379 flavonoid supplementation and acute exercise on SLC22 and other notable transporters in the
380 Organic Anion Transporter (OAT) and ATP-binding cassette (ABC) (transporter families), however,
381 is currently unknown. Limited rodent evidence indicates that exercise training upregulates the
382 expression of ABC transporters [20].

383 The intestinal microbiota has an important role in the metabolism of flavonoids, and lifestyle
384 interventions such as exercise and increased flavonoid intake have relatively rapid influences on
385 microbial diversity [21–23]. Physical exercise and fitness promote an anti-inflammatory state and this
386 may be one of several mechanisms that enhance intestinal microbial diversity [24]. Gut microbiota
387 are an essential component of flavonoid metabolism, and diversify when flavonoid ingestion
388 increases [21]. Although gut microbial diversity was not measured in the current study, the greater
389 concentration of plasma gut-derived phenolic metabolites in the runners and following acute exercise
390 bouts in flavonoid supplemented study participants may in part be coupled to greater intestinal
391 microbial diversity.

392 The pre-study cross-sectional comparison of the walkers and the leaner, more fit runners showed
393 that plasma gut-derived phenolic levels were 40% higher in the runners. These are novel results that
394 have not been previously reported. In another study, urinary excretion of colon-derived phenolic
395 catabolites after orange juice intake (one acute 0.5-liter dose) was slightly higher in the detrained
396 compared to trained state in a small group of endurance-trained males [6]. Additionally, the urinary
397 excretion rate for the trained males was lower than observed in a previous study with untrained
398 volunteers. Our data are in opposition to these findings for several potential reasons including the
399 use of different matrices (urine versus plasma) and more importantly, study designs. Additionally,
400 the current study measured a complex array of gut-derived phenolics versus a smaller panel focused
401 on orange juice-related metabolites.

402 Flavonoid supplementation and the related transient surge in gut-derived phenolics from either
403 walking or intensive running may over time lead to multiple health benefits (over and beyond the
404 direct effects of exercise alone). There is increasing evidence that gut-derived phenolics have wide
405 ranging bioactive effects on multiple enzyme systems, exerting anti-inflammatory, anti-viral, and
406 immune cell signaling influences, with enhancement of endothelial health and function in the
407 intestine and vasculature [1,25–30]. Our data indicate that gut-derived phenolics circulate at higher
408 levels throughout the body following flavonoid supplementation and exercise, potentially improving
409 long-term health and reducing the risk for chronic diseases.

410 To summarize from a public health viewpoint, this study utilized diet-relevant doses of
411 flavonoids combined with acute walking bouts. These changes are achievable by the broad spectrum
412 of the general population. This lifestyle stratagem was sufficient to transiently increase plasma levels
413 of beneficial gut-derived phenolics, an effect that was heightened with acute and chronic running.

414

415 **Supplementary Materials:** The following are available online, Table S1: Targeted Metabolomics Analysis
416 Reference Standards, and Table S2: Gut-Derived Phenolic Metabolites.

417 **Author Contributions:** Conceptualization, D.C.N., C.D.K., and M.A.L.; methodology, D.C.N., C.D.K., A.S.R.,
418 M.H.G., R.C.S., and M.A.L.; validation, C.D.K., A.S.R., R.C.S., and M.A.L.; formal analysis, D.C.N., C.D.K.,
419 A.S.R., M.H.G., R.C.S., and M.A.L.; investigation, D.C.N.; resources, D.C.N., C.D.K., and M.A.L.; data curation,
420 D.C.N., C.D.K., A.S.R., M.H.G., R.C.S., and M.A.L.; writing—original draft preparation, D.C.N., C.D.K., M.H.G.,
421 R.C.S., E.H.S., C.S., and M.A.L.; writing—review and editing, D.C.N., C.D.K., A.S.R., M.H.G., R.C.S., E.H.S., C.S.,
422 and M.A.L.; supervision, D.C.N., C.D.K., and M.A.L.; project administration, D.C.N., C.D.K., and M.A.L.;
423 funding acquisition, D.C.N.

424 **Funding:** This research was funded by Reoxcyn LLC, Pleasant Grove, UT 84062.

425 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the
426 study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
427 publish the results.

428

429 **References**

- 430 1. Williamson, G.; Kay, C. D.; Crozier, A. The bioavailability, transport, and bioactivity of dietary
431 flavonoids: a review from a historical perspective. *Comp. Rev. Food Sci. Food Saf.* **2018**, *17*, 1054–
432 1112, doi:10.1111/1541-4337.12351.
- 433 2. Nieman, D. C.; Gillitt, N. D.; Knab, A. M.; Shanely, R. A.; Pappan, K. L.; Jin, F.; Lila, M. A.
434 Influence of a polyphenol-enriched protein powder on exercise-induced inflammation and
435 oxidative stress in athletes: a randomized trial using a metabolomics approach. *PLoS ONE* **2013**,
436 *8*, e72215, doi:10.1371/journal.pone.0072215.
- 437 3. Lamprecht, M.; Frauwallner, A. Exercise, intestinal barrier dysfunction and probiotic
438 supplementation. *Med. Sport Sci.* **2012**, *59*, 47–56, doi:10.1159/000342169.
- 439 4. Dokladny, K.; Zuhl, M. N.; Moseley, P. L. Intestinal epithelial barrier function and tight junction
440 proteins with heat and exercise. *J. Appl. Physiol.* **2016**, *120*, 692–701,
441 doi:10.1152/jappphysiol.00536.2015.
- 442 5. Medina, S.; Domínguez-Perles, R.; García-Viguera, C.; Cejuela-Anta, R.; Martínez-Sanz, J. M.;
443 Ferreres, F.; Gil-Izquierdo, A. Physical activity increases the bioavailability of flavanones after
444 dietary aronia-citrus juice intake in triathletes. *Food Chem.* **2012**, *135*, 2133–2137,
445 doi:10.1016/j.foodchem.2012.07.080.
- 446 6. Pereira-Caro, G.; Polyviou, T.; Ludwig, I. A.; Nastase, A.-M.; Moreno-Rojas, J. M.; Garcia, A. L.;
447 Malkova, D.; Crozier, A. Bioavailability of orange juice (poly)phenols: the impact of short-term
448 cessation of training by male endurance athletes. *Am. J. Clin. Nutr.* **2017**, *106*, 791–800,
449 doi:10.3945/ajcn.116.149898.
- 450 7. Sebastian, R. S.; Wilkinson Enns, C.; Goldman, J. D.; Martin, C. L.; Steinfeldt, L. C.; Murayi, T.;
451 Moshfegh, A. J. A new database facilitates characterization of flavonoid intake, sources, and
452 positive associations with diet quality among US adults. *J. Nutr.* **2015**, *145*, 1239–1248,
453 doi:10.3945/jn.115.213025.
- 454 8. Gervasoni, J.; Schiattarella, A.; Giorgio, V.; Primiano, A.; Russo, C.; Tesori, V.; Scaldaferrì, F.;
455 Urbani, A.; Zuppi, C.; Persichilli, S. Validation of an LC-MS/MS method for urinary lactulose
456 and mannitol quantification: results in patients with irritable bowel syndrome. *Dis. Markers*
457 **2016**, *2016*, 5340386, doi:10.1155/2016/5340386.
- 458 9. Mishra, A.; Makharia, G. K. Techniques of functional and motility test: how to perform and
459 interpret intestinal permeability. *J. Neurogastroenterol. Motil.* **2012**, *18*, 443–447,
460 doi:10.5056/jnm.2012.18.4.443.
- 461 10. Nieman, D. C.; Ramamoorthy, S.; Kay, C. D.; Goodman, C. L.; Capps, C. R.; Shue, Z. L.; Heyl,
462 N.; Grace, M. H.; Lila, M. A. Influence of ingesting a flavonoid-rich supplement on the
463 metabolome and concentration of urine phenolics in overweight/obese women. *J. Proteome Res.*
464 **2017**, *16*, 2924–2935, doi:10.1021/acs.jproteome.7b00196.
- 465 11. Karl, J. P.; Margolis, L. M.; Madslie, E. H.; Murphy, N. E.; Castellani, J. W.; Gundersen, Y.;
466 Hoke, A. V.; Levangie, M. W.; Kumar, R.; Chakraborty, N.; Gautam, A.; Hammamieh, R.;
467 Martini, S.; Montain, S. J.; Pasiakos, S. M. Changes in intestinal microbiota composition and
468 metabolism coincide with increased intestinal permeability in young adults under prolonged
469 physiological stress. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2017**, *312*, G559–G571,
470 doi:10.1152/ajpgi.00066.2017.

- 471 12. Lai, R. E.; Jay, C. E.; Sweet, D. H. Organic solute carrier 22 (SLC22) family: Potential for
472 interactions with food, herbal/dietary supplements, endogenous compounds, and drugs. *J. Food*
473 *Drug Anal.* **2018**, *26*, S45–S60, doi:10.1016/j.jfda.2018.03.002.
- 474 13. Oteiza, P. I.; Fraga, C. G.; Mills, D. A.; Taft, D. H. Flavonoids and the gastrointestinal tract: Local
475 and systemic effects. *Mol. Aspects Med.* **2018**, *61*, 41–49, doi:10.1016/j.mam.2018.01.001.
- 476 14. Valenzano, M. C.; DiGuilio, K.; Mercado, J.; Teter, M.; To, J.; Ferraro, B.; Mixson, B.; Manley, I.;
477 Baker, V.; Moore, B. A.; Wertheimer, J.; Mullin, J. M. Remodeling of tight junctions and
478 enhancement of barrier integrity of the CACO-2 intestinal epithelial cell layer by
479 micronutrients. *PLoS ONE* **2015**, *10*, e0133926, doi:10.1371/journal.pone.0133926.
- 480 15. Cremonini, E.; Mastaloudis, A.; Hester, S. N.; Verstraeten, S. V.; Anderson, M.; Wood, S. M.;
481 Waterhouse, A. L.; Fraga, C. G.; Oteiza, P. I. Anthocyanins inhibit tumor necrosis alpha-induced
482 loss of Caco-2 cell barrier integrity. *Food Funct.* **2017**, *8*, 2915–2923, doi:10.1039/c7fo00625j.
- 483 16. Al-Sadi, R.; Ye, D.; Boivin, M.; Guo, S.; Hashimi, M.; Ereifej, L.; Ma, T. Y. Interleukin-6
484 modulation of intestinal epithelial tight junction permeability is mediated by JNK pathway
485 activation of claudin-2 gene. *PLoS ONE* **2014**, *9*, e85345, doi:10.1371/journal.pone.0085345.
- 486 17. Al-Sadi, R.; Boivin, M.; Ma, T. Mechanism of cytokine modulation of epithelial tight junction
487 barrier. *Front. Biosci. (Landmark Ed)* **2009**, *14*, 2765–2778.
- 488 18. Murota, K.; Nakamura, Y.; Uehara, M. Flavonoid metabolism: the interaction of metabolites
489 and gut microbiota. *Biosci. Biotechnol. Biochem.* **2018**, *82*, 600–610,
490 doi:10.1080/09168451.2018.1444467.
- 491 19. Nigam, S. K. The SLC22 transporter family: a paradigm for the impact of drug transporters on
492 metabolic pathways, signaling, and disease. *Annu. Rev. Pharmacol. Toxicol.* **2018**, *58*, 663–687,
493 doi:10.1146/annurev-pharmtox-010617-052713.
- 494 20. Morton, A. B.; Mor Huertas, A.; Hinkley, J. M.; Ichinoseki-Sekine, N.; Christou, D. D.; Smuder,
495 A. J. Mitochondrial accumulation of doxorubicin in cardiac and diaphragm muscle following
496 exercise preconditioning. *Mitochondrion* **2018**, doi:10.1016/j.mito.2018.02.005.
- 497 21. Kardum, N.; Glibetic, M. Polyphenols and their interactions with other dietary compounds:
498 implications for human health. *Adv. Food Nutr. Res.* **2018**, *84*, 103–144,
499 doi:10.1016/bs.afnr.2017.12.001.
- 500 22. Clarke, S. F.; Murphy, E. F.; O’Sullivan, O.; Lucey, A. J.; Humphreys, M.; Hogan, A.; Hayes, P.;
501 O’Reilly, M.; Jeffery, I. B.; Wood-Martin, R.; Kerins, D. M.; Quigley, E.; Ross, R. P.; O’Toole, P.
502 W.; Molloy, M. G.; Falvey, E.; Shanahan, F.; Cotter, P. D. Exercise and associated dietary
503 extremes impact on gut microbial diversity. *Gut* **2014**, *63*, 1913–1920, doi:10.1136/gutjnl-2013-
504 306541.
- 505 23. Estaki, M.; Pither, J.; Baumeister, P.; Little, J. P.; Gill, S. K.; Ghosh, S.; Ahmadi-Vand, Z.;
506 Marsden, K. R.; Gibson, D. L. Cardiorespiratory fitness as a predictor of intestinal microbial
507 diversity and distinct metagenomic functions. *Microbiome* **2016**, *4*, 42, doi:10.1186/s40168-016-
508 0189-7.
- 509 24. Codella, R.; Luzi, L.; Terruzzi, I. Exercise has the guts: How physical activity may positively
510 modulate gut microbiota in chronic and immune-based diseases. *Dig. Liver Dis.* **2018**, *50*, 331–
511 341, doi:10.1016/j.dld.2017.11.016.

- 512 25. Ahmed, M.; Henson, D. A.; Sanderson, M. C.; Nieman, D. C.; Gillitt, N. D.; Lila, M. A. The
513 protective effects of a polyphenol-enriched protein powder on exercise-induced susceptibility
514 to virus infection. *Phytother. Res.* **2014**, *28*, 1829–1836, doi:10.1002/ptr.5208.
- 515 26. Amin, H. P.; Czank, C.; Raheem, S.; Zhang, Q.; Botting, N. P.; Cassidy, A.; Kay, C. D.
516 Anthocyanins and their physiologically relevant metabolites alter the expression of IL-6 and
517 VCAM-1 in CD40L and oxidized LDL challenged vascular endothelial cells. *Mol. Nutr. Food Res.*
518 **2015**, *59*, 1095–1106, doi:10.1002/mnfr.201400803.
- 519 27. di Gesso, J. L.; Kerr, J. S.; Zhang, Q.; Raheem, S.; Yalamanchili, S. K.; O'Hagan, D.; Kay, C. D.;
520 O'Connell, M. A. Flavonoid metabolites reduce tumor necrosis factor- α secretion to a greater
521 extent than their precursor compounds in human THP-1 monocytes. *Mol. Nutr. Food Res.* **2015**,
522 *59*, 1143–1154, doi:10.1002/mnfr.201400799.
- 523 28. Edwards, M.; Czank, C.; Woodward, G. M.; Cassidy, A.; Kay, C. D. Phenolic metabolites of
524 anthocyanins modulate mechanisms of endothelial function. *J. Agric. Food Chem.* **2015**, *63*, 2423–
525 2431, doi:10.1021/jf5041993.
- 526 29. Kay, C. D. Rethinking paradigms for studying mechanisms of action of plant bioactives. *Nutr.*
527 *Bull.* **2015**, *40*, 335–339, doi:10.1111/nbu.12178.
- 528 30. Warner, E. F.; Smith, M. J.; Zhang, Q.; Raheem, K. S.; O'Hagan, D.; O'Connell, M. A.; Kay, C. D.
529 Signatures of anthocyanin metabolites identified in humans inhibit biomarkers of vascular
530 inflammation in human endothelial cells. *Mol. Nutr. Food Res.* **2017**, *61*,
531 doi:10.1002/mnfr.201700053.